** Drug developer Disc Medicine's IRON.O shares fall ~5% to $59.46
** Company says in filing it expects to report material weakness in its internal control over financial reporting for year ending Dec. 31, 2024
** Disc Medicine adds issue due to ineffective Information Technology General Controls (ITGC) - policies aimed at keeping the company's IT systems secure and working properly - over some key financial IT systems
** Company says no misstatements have been identified in its financial statements so far
** Disc Medicine says its auditor has not completed the audit of its internal controls and cannot provide an opinion yet
** All 11 brokerages rate the stock "buy" or higher; median PT $90 - LSEG
** Company's shares gained 6.1% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.